Oncolytics: the dawn of a new era in cancer treatment
No other industry would tolerate avoidable annual losses of $637 billion, but that’s exactly what pharma is doing by not investing in adherence. Now is the time to start recovering that revenue.
There are good reasons why patient centricity has become such a well-used term within the pharmaceutical industry. But, says Kantar Health’s Linda VerPlanck, the research approaches underpinning it must be able to deliver transformational insights that can, in turn, improve real-world outcomes.
How can pharma marketers put patients at the centre of product strategy and help improve their conditions?
In the latest edition of our Deep Dive magazine – Deep Dive: Patient Centricity II – David Mitchell, President of Patients For Affordable Drugs, speaks to pharmaphorum’s Andrew McConaghie about why the organisation was set up and why its campaigning work is so important for patients.
A review of some of the cutting-edge start-ups and key themes that were evident at the Frontiers Health event.
Digital technologies are both helping to transform the public’s perception of dementia, and enabling everyone to help scientific research into the disease by playing a smartphone game that tests navigation skills.